|
|
|
| Relationship between Baseline Level of Serum CCL11 and CCL18 with Clinicopathological Features and Recurrence of Differentiated Thyroid Carcinoma and Their Predictive Value |
| LI Dongdong, ZHENG Chen, ZHENG Erliang |
| Xi'an Central Hospital, Shaanxi Xi'an 710000, China |
|
|
|
|
Abstract Objective: To analyze the relationship between the baseline level of serum C-C motif chemokine ligand 11 (CCL11) and C-C motif chemokine ligand 18 (CCL18) with clinicopathological features and recurrence of differentiated thyroid cancer (DTC), thus analyzing the predictive value of CCL11 and CCL18 levels for recurrence. Methods: One hundred and fifty-one patients with DTC in the hospital from March 2020 to March 2023 were enrolled. The baseline date of Serum CCL11 and CCL18 levels were measured. According to whether or not the recurrence at 1 year of surgery, they were classified into the recurrence group (n=35) and the non-recurrence group (n=116). The baseline levels of serum CCL11 and CCL18 were compared among patients with different clinicopathological characteristics. The predictive value of baseline levels of serum CCL11 and CCL18 levels in evaluating postoperative recurrence was analyzed by receiver operating characteristic curve (ROC). Results: The preoperative serum CCL11 and CCL18 levels were significantly higher in the recurrence group than in the non-recurrence group (P<0.05). Baseline levels of serum CCL11 and CCL18 were associated with lymph node metastasis, depth of invasion, and the tumor-node-metastasis (TNM) staging (P<0.05), but were not related to number of lesions, and microcalcification inside the tumor (P>0.05). ROC curve demonstrated that the area under the curve (AUC) of baseline levels of serum CCL11 and CCL18 alone and in combination in predicting postoperative recurrence of DTC was 0.612, 0.725 and 0.892, with sensitivities of 71.43%, 77.14% and 80.00% and specificities of 55.17%, 62.21% and 90.52% respectively. The efficiency of combined prediction was better than that of each indicator alone (P<0.05). Conclusion: The baseline levels of serum CCL11 and CCL18 are closely related to the clinicopathological characteristics and recurrence of patients with DTC. Measuring preoperative serum CCL11 and CCL18 levels can provide a certain predictive value on postoperative recurrence of the patients.
|
|
|
|
|
|
[1] Schlumberger M,Leboulleux S.Current practice in patients with differentiated thyroid cancer[J].Nat Rev Endocrinol,2021,17(3):176-188.
[2] Polosukhina D,Singh K,Asim M,et al.CCL11 exacerbates colitis and inflammation-associated colon tumorigenesis[J].Oncogene,2021,40(47):6540-6546.
[3] Zhou M,Yu H,Bai M,et al.IRG1 restrains M2 macrophage polarization and suppresses intrahepatic cholangiocarcinoma progression via the CCL18/STAT3 pathway[J].Cancer Sci,2024,115(3):777-790.
[4] Shibata M,Inaishi T,Ichikawa T,et al.Identifying the tumor-progressive gene expression profile in high-risk papillary thyroid cancer[J].Surg Today,2021,51(10):1703-1712.
[5] Korbecki J,Olbromski M,Dzigiel P.CCL18 in the progression of cancer[J].Int Mol Sci,2020,21(21):7955-7979.
[6] 华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华核医学与分子影像杂志,2013,33(2):96-115.
[7] Nabhan F,Dedhia PH,Ringel MD.Thyroid cancer,recent advances in diagnosis and therapy[J].Int Cancer,2021,149(5):984-992.
[8] 张瑜,马征泽,王曼,等.甲状腺癌组织中TIPE2、LASP1蛋白表达与其临床病理特征及预后的相关性分析[J].实用癌症杂志,2024,39(1):10-13.
[9] 黄冠又,葛学成,甘鸿川,等.CCL18在胶质母细胞瘤中的表达及其对U87MG细胞增殖和迁移的影响[J].天津医药,2023,51(9):915-921.
[10] 臧荣发,顾盼瑾,尤建良.联合检测血清galectin-3、sIL-2R、CCL11表达水平在评估结肠癌患者预后中的价值研究[J].河北医药,2019,41(10):1460-1463,1468.
[11] Huang X,Lai S,Qu F,et al.CCL18 promotes breast cancer progression by exosomal miR-760 activation of ARF6/Src/PI3K/Akt pathway[J].Mol Ther Oncolytics,2022(25):1-15.
[12] 张福明,张祎苒,王萌,等.CCL11、MK对分化型甲状腺癌患者预后的评估价值[J].解放军医学杂志,2023,48(9):1048-1054.
[13] Sun C,Wang P,Gao T,et al.CCL18 knockdown suppresses cell growth and migration in thyroid cancer[J].Healthc Eng,2022(2022):154-155. |
|
|
|
2025, Vol. 31 
